media – Page 266 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Innovent Biologics’ “IL-4Rα/TSLP Dual Antibody” Applies for Clinical Trial in China

On December 7, according to the official website of CDE, the clinical trial application of Innovent Biologics’ Class 1 new drug IBI3002 was accepted. According to public information, IBI3002 is a FIC bispecific antibody targeting IL-4Rα and TSLP. Asthma is a heterogeneous disease mediated by a variety of immune cells, cytokines and inflammatory mediators, affecting people of all ages, characterized by a variety of symptoms such as wheezing, shortness of breath, cough and chest tightness, with hundreds of millions of patients worldwide. Drug treatment is one of the important means to relieve and control asthma. The IL-4 receptor mediates the IL-4 signaling pathway (type 1 and type 2) and the IL-13 signaling pathway (type 2), and both cytokine signaling pathways play a key role in the pathophysiology of type 2 inflammatory diseases. TSLP is an epithelial cell-derived alarmin cytokine that triggers type 2 and non-type 2 inflammation in asthma. According ...
- Source: drugdu
- 508
- December 13, 2024
The world’s first valve disruptor plans IPO

Australian innovative structured heart disease listed company Anteris Technologies (ASX: AVR) officially announced today that it has launched its initial public offering (IPO) in the United States, planning to issue 14.8 million shares at a price of $6.78 per share to raise $100 million. According to the proposed price, the market value of Anteris Technologies will reach $244 million (approximately RMB 1.77 billion). The funds raised will fully promote the research and development process of its innovative DurAVR transcatheter heart valve technology. This product is the world’s first integrated leaflet aortic valve using a single piece of biological tissue engineering, resulting in lower mechanical stress, optimal hemodynamics, and the ability to mimic the performance of healthy human aortic valves. The company calls it the TAVR that shapes the future and is highly regarded in the medical community. The IPO plans to issue 14.8 million ordinary shares and grant underwriters the ...
- Source: drugdu
- 444
- December 12, 2024
Fujifilm, Shining Oriental Digestive Endoscopy Academic Conference

01. Conference Introduction The 5th Oriental Digestive Endoscopy Academic Conference, hosted by the Shanghai Medical Association and the Digestive Endoscopy Branch of the Shanghai Medical Association, and co organized by the First Affiliated Hospital of Naval Medical University, Huashan Hospital affiliated with Fudan University, and Zhongshan Hospital affiliated with Fudan University, was successfully held in Shanghai from November 22nd to 24th. This conference, with the concept of “integrating innovation and pursuing excellence”, has gathered more than a thousand experts and scholars in the field of digestion. Led by endoscopy in the diagnosis and treatment of major digestive diseases, it adopts a multidisciplinary and multi forum joint meeting to jointly explore and share clinical experience and the latest research results in the field of digestion. It can be said that it is a perfect combination and complement each other. 02. Various highlights of the booth As an important event in the ...
- Source: drugdu
- 380
- December 12, 2024
Recently, the traditional Chinese medicine industry has been heavily involved in mergers and acquisitions, with multiple companies “crossing boundaries” to layout biochemical innovative drugs

This year, traditional Chinese medicine companies have been intensively involved in mergers and acquisitions. Since August, listed Chinese medicine companies such as Lingrui Pharmaceutical, Kangyuan Pharmaceutical, Pianzaihuang, and CR Sanjiu have announced their merger and acquisition plans. At the same time, the recent establishment of investment funds by Yunnan Baiyao and Pianzaihuang is also considered a prelude to outward mergers and acquisitions. Li Zhong, a senior marketing expert in the pharmaceutical industry, stated in an interview with 21st Century Business Herald that the integration of the entire traditional Chinese medicine industry is inevitable and belongs to the national strategic direction. Large traditional Chinese medicine enterprises may increase their integration efforts, and the industry will present a stronger and stronger force. Traditional Chinese medicine enterprises with well-known brands, good products, good teams, and good research and development will develop rapidly. At the same time, some small enterprises will naturally be integrated, ...
- Source: drugdu
- 520
- December 12, 2024
K Med Expo

Organiser：KINTEX Co., Ltd. Time： July 10 – 12, 2025 Address：No. 57 Pham Hung, Me Tri, Tu Liem, Hanoi, Vietnam Exhibition hall：National Convention Center Product range: Medical Equipment: Diagnostic, examination, and treatment equipment; accident and emergency equipment; diagnostic, sterilization, and disposal systems; electronic medical equipment; medical technology; medical furniture and equipment; rehabilitation equipment; orthopedic supplies; medical consumables; dental materials and equipment Pharmaceutical Equipment: Pharmaceuticals; machinery, equipment, and technology for the research, development, and production of pharmaceutical materials and packaging; products and equipment provided by R&D departments; aesthetic equipment, aesthetic care, and high-quality medical services About K Med Expo： The Vietnam Medical Equipment and Pharmaceutical Exhibition (K Med Expo) has gradually emerged as the most specialized international exhibition in the medical and pharmaceutical fields in Vietnam. Due to its professionalism and high-quality professional audience, it has attracted an increasing number of foreign enterprises, including those from China, to enter the Vietnamese ...
- Source: drugdu
- 462
- December 12, 2024
The first domestic drug for treating Duchenne muscular dystrophy, Angelide ® Approved for listing

On December 11, 2024, Shufang Medicine announced the announcement of Anjiali ® (Common name: Vamorolone Oral Suspension, Vamorolone); Specification: 40mg/mL, 100mL/bottle) has recently been approved by the National Medical Products Administration (NMPA) of China for the treatment of Duchenne muscular dystrophy (DMD) patients aged four years and above. Angali ® It is the first domestically approved treatment drug for Duchenne muscular dystrophy. Angali ® Previously, it was included in the breakthrough treatment drug and priority review procedures by the Drug Evaluation Center of the National Medical Products Administration.Duchenne muscular dystrophy is a rare neuromuscular disease that often occurs in childhood, and there is a huge unmet medical need in this field. Angali ® It is the first DMD treatment drug that has been fully approved in both the United States and the European Union. Its receptor that binds to glucocorticoids is the same, but its downstream activity is altered. Compared ...
- Source: drugdu
- 566
- December 12, 2024
GLP-1 fired a shot at the AD market?

As we all know, Alzheimer’s disease is still one of the most difficult diseases in the world. The core is that the medical community still knows very little about its pathogenesis. There are currently two mainstream hypotheses about the mechanism of Alzheimer’s disease: One is the Aβ hypothesis, that is, the overexpression of β-amyloid protein (Aβ) aggregates into amyloid plaques; the other is the Tau protein hypothesis, that is, the neurofibrillary tangles formed by the misfolding of Tau protein after excessive phosphorylation. Regardless of which hypothesis, countless pharmaceutical companies have failed frequently, including the Aβ hypothesis that is most recognized by pharmaceutical companies. According to this hypothesis, the more completely the drug clears the amyloid plaques in the patient’s brain, the more beneficial it is for controlling the development of the disease. Donanemab and lecanemab, which have been approved, are the same, but the mechanisms are different. How much benefit ...
- Source: drugdu
- 467
- December 11, 2024
China’s gene sequencing industry survives the darkest moment

When it comes to the major issue of China’s gene sequencing industry, the Biosafety Act is an unavoidable topic. At the beginning of the year, in the draft version of the Biosafety Act submitted by members of the U.S. House of Representatives, domestic companies such as WuXi AppTec, BGI, and BGI were mentioned; a similar draft bill was recently proposed by the U.S. Senate. If these bills are passed, medical institutions funded by the U.S. government will be restricted from using the products and technologies of the mentioned companies. Therefore, the Biosafety Act inevitably caused excessive panic in the domestic capital market, causing some companies to oversell. Since the “924 market”, the Science and Technology Innovation 50 has been a weather vane, with a cumulative increase of nearly 20%. Although BGI is a component of the Science and Technology Innovation 50, its stock price has fallen by nearly 40% since ...
- Source: drugdu
- 379
- December 11, 2024
【EXPERT Q&A】Do I need to obtain authorization for the same type of medical device information?

Drugdu.com expert’s response: During the medical device registration or filing process, if the proposed referenced data for the same kind of medical device (including technical documents, clinical trial data, market usage information, etc.) are non-public, meaning these data have not been released through public channels and are protected by intellectual property rights (such as patents, trade secrets, etc.), authorization or permission from the original data holder is typically required to ensure the legitimacy and compliance of the data. This is because unauthorized use of non-public data may infringe upon the intellectual property rights of the original data holder, leading to legal disputes and regulatory risks. Therefore, when submitting a medical device registration or filing application, corresponding authorization documents or certificates should be attached to prove that the data used were legally obtained. However, if the data for the same kind of medical device are publicly published data, such as those ...
- Source: drugdu
- 377
- December 11, 2024
Behind the sales difference between China and the United States

When it comes to innovative anesthetic sedative drugs launched in recent years, remimazolam is undoubtedly a variety worthy of attention. Remimazolam was designed and synthesized by GSK in 1999. After changing hands many times, it was approved for marketing in China, the United States, Europe and other countries almost simultaneously around 2020. However, the author found that the sales volume of the drug after its launch in different countries varies greatly. In 2023, the sales volume of remimazolam in China was about 40 million US dollars, while that in the United States was only 800,000 US dollars, which is about 2% of the Chinese market. Why is there such a difference? It is reported that remimazolam, a “new star” in the field of anesthesia, is an ultra-short-acting GABAA receptor agonist that combines the characteristics of midazolam and remifentanil, two anesthetics. Like midazolam, it acts on GABA receptors, but like remifentanil, ...
- Source: drugdu
- 457
- December 11, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.